ENZO BIOCHEM INC Form 8-K November 17, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 17, 2015
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in Its Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202 (Commission File Number) (IRS Employer Identification No.)

**527 Madison Avenue** 

New York, New York 10022 (Address of Principal Executive Offices) (Zip Code)
(212) 583-0100
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( <i>see</i> General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240 13e-4(c))

2

#### **Item 8.01 Other events**

On November 17, 2015, Enzo Biochem, Inc. (the "Company") issued a press release announcing New York State approval of its first assay based on Ampiprobe<sup>TM</sup> platform aimed at providing affordable molecular diagnostics in light of reimbursement pressure.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Enzo Biochem, Inc., dated November 17, 2015.

3

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### ENZO BIOCHEM, INC.

Date: November 17, 2015 By:/s/ Barry W. Weiner Barry W. Weiner President

4